市场调查报告书
商品编码
921868

全球过敏治疗市场:成长,趋势,及预测(2020年~2025年)

Allergy Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 125 Pages | 商品交期: 2-3个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

  • 全貌
  • 简介
  • 目录
简介

全球过敏治疗市场增长的关键因素包括过敏治疗负担的增加,制造商对开发新过敏治疗的投资的增加以及自我药物治疗的重要性日益增加。此外,皮下免疫疗法(SCIT)是最常用的过敏性免疫疗法,并且具有高增长率。越来越多的免疫疗法批准是市场增长的主要动力。

本报告提供全球过敏治疗市场的相关调查,提供市场机会和趋势,成长及阻碍因素,各类型·治疗·地区的市场分析,竞争情形,主要企业的简介等资讯。

目录

第1章 简介

  • 调查成果
  • 调查的前提条件
  • 调查范围

第2章 调查方法

第3章 摘要整理

第4章 市场动态

  • 市场概况
  • 市场成长要素
    • 自我用药的重要性日益增加
    • 全球食物过敏的发生率在增加
    • 增加制造商对开发新的过敏疗法的投资
  • 市场阻碍因素
    • 生物相似药的使用的偏好的高涨
    • 患者缺乏对过敏免疫疗法(AIT)的认识
  • 波特的五力分析

第5章 市场区隔

  • 各类型
    • 眼的过敏
    • 鼻炎
    • 气喘
    • 皮肤过敏
    • 食物过敏
    • 其他
  • 不同治疗
    • 抗过敏药
    • 免疫疗法
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第6章 竞争情形

  • 企业简介
    • ALK-Abello A/S
    • Allergy Therapeutics
    • Sanofi SA
    • Allergan Plc.
    • Merck KGaA (Allergopharma)
    • F. Hoffmann-La Roche Ltd. (Genentech Inc.)
    • Stallergenes Greer plc
    • Johnson & Johnson
    • GlaxoSmithKline plc
    • Leti Pharma

第7章 市场机会及今后趋势

目录
Product Code: 67344

The Allergy Treatment Market was valued at USD 18,055 million in 2020 and is expected to reach USD 26,196.62 million by 2026, registering a CAGR of 6.4% during the forecast period.

With the onset of the COVID-19 pandemic, it was found that a large section of people, globally, have been struggling with chronic respiratory issues, such as respiratory allergies, including allergic rhinitis and sinusitis. For instance, a survey conducted by the Asthma and Allergy Foundation of America in June 2020, stated that 2,695 people were made to participate in the study out of which 57% have asthma, 51% have a family member with asthma, 63% have allergies, and 66% have a family member with allergies, within the survey group. Thus, the impact of COVID-19 is so far considered positive on the market.

The increasing burden of various types of allergies, growing investment by the manufacturers on the development of novel allergic treatments, and rising importance for self-medication are the major factors propelling the growth of the market. A 2020 report by the Food Allergy Research & Education estimates that 32 million US residents have food allergies, including 5.6 million children under age 18. About 40% of children with food allergies are allergic to more than one food.

As per the data published by the American College of Allergy, Asthma & Immunology, allergies are the sixth leading cause of chronic illness in the United States, with an annual cost of more than USD 18 billion, and more than 50 million Americans suffer from allergies each year. Food allergies among both children and adults are increasing in all parts of the world. Thus, this surge in the burden of allergic diseases is expected to increase the demand for allergy treatment. Moreover, the increasing focus on research and development to develop novel products to cater to high unmet medical needs present currently in the market serves to be the high impact driver for the growth of the market. For instance, in April 2020, Menlo Therapeutics Inc. reported positive results from its two ongoing Phase-III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of Pruritus, a type of skin allergy.

Also, the trend of self-medication has been increasingly adopted by the population in both developed and developing countries the Hence, because of all self-medication the increase in over-the-counter (OTC) drugs has been seen over the past decade. These OTC drugs are cheaper and more accessible to a large number of patients which directly increases the procurement of these drugs. All these factors are expected to propel the market growth in the forecasted period. However, a rise in preference towards low-cost biosimilar and low awareness regarding allergy immunotherapy can hamper the market growth.

Key Market Trends

Subcutaneous Immunotherapy (SCIT) is Expected to Register a High Growth Rate During the Forecast Period

Subcutaneous immunotherapy (SCIT), is the most effective and widely used allergy immunotherapy. So far SCIT is the only treatment that alters the immune systems and brings systemic relief. SCIT helps to prevent the further development of new allergies and asthma.

The innovative launch of immunotherapy products and rising approval are the major factors boosting the growth of the market. For instance, recently, in October 2019, ALK-Abello AS secured an amended regulatory approval in Germany for its SCIT product, Alutard SQ, sold in Germany, under the brand name ALK-depot SQ, for allowing a shorter up-dosing for the product.

Also, in 2018, Stallergenes Greer received United States Food and Drug Administration (FDA) approval for the extended indication of the Oralair, an allergy immunotherapy sublingual tablet, for the treatment of grass pollen-induced allergic rhinitis in children aged 5 to 9-year-old. Moreover, immunotherapy has attracted various government initiatives for instance in January 2018, the Ministry and the Japanese Society of Allergology opened a dedicated website about allergies in order to create awareness about the allergy and various immunotherapy. Thus, the rising burden of allergies coupled with the growing adoption of immunotherapy among the population is expected to drive the market growth.

North America is Expected to Dominate the Allergy Treatment Market

North America is expected to dominate the market accounting for the highest share and is anticipated to maintain this trend throughout the forecast period. According to an article published in JAMA Network Open Journal, an estimated 10.8% were food allergic at the time of the survey, whereas nearly 19% of adults believed that they were food allergic. Nearly half of food-allergic adults had at least 1 adult-onset food allergy, and 38% reported at least 1 food allergy-related emergency department visit in their lifetime. Also, according to the Asthma and Allergy Foundation of America, peanut causes the highest number of food allergies (1.6 million children in 2018, as per Food Allergy Research and Education). Sesame was the ninth-most common food allergy in the United States, as per the American Academy of Allergy Asthma and Immunology. This prevalence is very high and is anticipated to further increase in the future to come.

Apart from the United States, the government of Canada is also focusing on providing Canadians with the information they require to make healthy and safe food choices. The CFIA (Canadian Food Inspection Agency) and Health Canada work jointly with provincial, municipal, and territorial partners and industries to reach this goal.

Moreover, in the United States, numerous drugs are under development, primarily to treat various types of allergies. Market players are focusing on the development and launch of new products. In March 2019, Aimmune Therapeutics Inc.'s Biologics License Application (BLA) for AR101 was accepted for review by the US Food and Drug Administration (FDA). The focus on R&D, primarily for the introduction of better products, is anticipated to drive the US allergy treatment market's growth during the forecast period.

Competitive Landscape

The majority of the allergy treatment products are being manufactured by the global key players. The market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness and this has also helped the market to grow.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 The Increasing Importance for Self-medication
    • 4.2.2 Rising Incidence of Food Allergies Across the Globe
    • 4.2.3 Rising Investments by the Manufacturers on the Development of Novel Allergic Treatments
  • 4.3 Market Restraints
    • 4.3.1 Rise in Preference Towards the Use of Biosimilars
    • 4.3.2 Low Awareness of Allergy Immunotherapy (AIT) Among Patients
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Eye Allergy
    • 5.1.2 Rhinitis
    • 5.1.3 Asthma
    • 5.1.4 Skin Allergy
    • 5.1.5 Food Allergies
    • 5.1.6 Other Allergies
  • 5.2 By Treatment
    • 5.2.1 Anti-Allergy Drugs
      • 5.2.1.1 Antihistamines
      • 5.2.1.2 Corticosteroids
      • 5.2.1.3 Decongestants
      • 5.2.1.4 Other Drugs
    • 5.2.2 Immunotherapy
      • 5.2.2.1 Sub-cutaneous Immunotherapy (SCIT)
      • 5.2.2.2 Sub-Lingual Immunotherapy (SLIT)
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ALK-Abello A/S
    • 6.1.2 AbbVie Inc.
    • 6.1.3 Allergy Therapeutics
    • 6.1.4 Anacor Pharmaceuticals Inc.
    • 6.1.5 AstraZeneca
    • 6.1.6 F. Hoffmann-La Roche Ltd. (Genentech Inc.)
    • 6.1.7 Galderma S.A.
    • 6.1.8 GlaxoSmithKline plc
    • 6.1.9 Johnson & Johnson
    • 6.1.10 Leti Pharma
    • 6.1.11 Merck KGaA (Allergopharma)
    • 6.1.12 Novartis International AG
    • 6.1.13 Sanofi SA
    • 6.1.14 Stallergenes Greer plc
    • 6.1.15 Teva Pharmaceutical Industries

7 MARKET OPPORTUNITIES AND FUTURE TRENDS